Company Overview
Satellos Bioscience Inc. (NASDAQ: MSLE) is a clinical-stage biotechnology company focused on developing SAT-3247 to treat degenerative muscle diseases like Duchenne muscular dystrophy. The company recently transitioned to the Nasdaq Global Market in February 2026.
Key Financial Figures
For the year ended December 31, 2025, Satellos reported a net loss of $24.9 million, resulting in an EPS of $1.70 loss per basic and diluted common share. Revenue figures were not disclosed in the report.
Additional Financial Insights
Cash reserves totaled $27.7 million at year-end 2025. However, a subsequent $57.2 million equity financing in early 2026 is expected to extend the company’s cash runway through 2027.